View ValuationRegentis Biomaterials 향후 성장Future 기준 점검 0/6현재 Regentis Biomaterials 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.핵심 정보n/a이익 성장률n/aEPS 성장률Biotechs 이익 성장25.4%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트02 Mar 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 12hRegentis Biomaterials Ltd. announced that it expects to receive $6.5 million in fundingRegentis Biomaterials Ltd. entered into definitive securities purchase agreements with certain accredited and institutional investors for issuance of 1,844,543 common shares at a price of $3.50 per share for gross proceeds of $6,455,900.50; and 12,600 pre-funded warrants at a price of $3.4999 per pre-funded warrant for gross proceeds of $44,098.74; for aggregate gross proceeds of $6,499,999.24 on June 17, 2026. The company will also issue ordinary warrants to purchase up to 1,857,143 ordinary shares. The pre-funded warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable upon issuance and will not expire until exercised in full. The ordinary warrants have an exercise price of $4.20 per ordinary share, are immediately exercisable upon issuance and will expire on the five-year anniversary from the date of issuance. The offering is expected to close on or about June 23, 2026. The ordinary shares, the warrants and the ordinary shares issuable upon exercise of the warrants were offered and sold pursuant to an exemption from the registration requirements of the securities act of 1933, as amended, under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D promulgated thereunder.공시 • Jun 15Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21공시 • Jun 09Regentis Biomaterials Ltd. Commences European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations AccelerateRegentis Biomaterials Ltd. announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC in Europe, where it has CE Mark approval. The hands-on training program is designed to train orthopedic surgeons in the use of GelrinC, providing practical experience with the implantation procedure and supporting physician readiness ahead of market launch. The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital. Additional sessions are planned in other European markets. GelrinC is a cell-free implant for the treatment of knee cartilage lesions. The procedure utilizes a ready-to-use implant and a straightforward single-step implantation process, which takes approximately 10 minutes, and fits into the surgeon's workflow. Regentis is establishing a network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC. These centers are intended to serve as clinical hubs where experienced orthopedic surgeons will help train and support other physicians across Europe as the technology is introduced into clinical practice. Regentis is targeting an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus standard of care microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration study, which has completed over 50% enrollment.공시 • May 29Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026. Location: apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal, tel aviv, IsraelNew Risk • May 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$10.00m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$10.00m market cap).공시 • May 03Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21New Risk • Feb 26New major risk - Revenue and earnings growthEarnings have declined by 5.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$20.7m market cap).공시 • Feb 04+ 1 more updateRegentis Biomaterials Ltd. Announces the Appointment of Ori Gon as Chief Financial Officer, Effective February 4, 2026Regentis Biomaterials Ltd. announced the appointment of Ori Gon as Chief Financial Officer, effective February 4, 2026. Mr. Gon will lead the Company's commercial and business development activities, as well as its financial strategy, planning, and reporting. Mr. Gon joins Regentis at a pivotal time as GelrinC®, the Company's proprietary hydrogel implant for knee cartilage repair, advances towards commercial launch in Europe following CE Mark approval and is being evaluated in a pivotal Phase III FDA clinical trial in the United States. Mr. Gon brings over 15 years of financial leadership experience across public and private enterprises and medical technology. Most recently, he served as CFO at Tactile Mobility, a sensing and data analytics company focused on advanced automotive and mobility applications. Prior to that, he held senior financial leadership roles at ReWalk Robotics Inc., now Nasdaq-listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons for individuals with lower limb disabilities, where he served as CFO and Corporate Controller. Earlier in his career, he was Controller at On Track Innovations Ltd., a Nasdaq- and Neuer Markt-listed fintech company. He began his professional career as an auditor at KPMG Israel. Mr. Gon has led multiple secondary public offerings and financing transactions across various structures, raising over $150 million in aggregate capital. He is a Certified Public Accountant (CPA) in Israel.공시 • Jan 21Regentis Biomaterials Ltd. Announces New Long-Term Imaging Data from Its Successfully Completed European Clinical Trial of GelrinCRegentis Biomaterials Ltd. announced new long-term imaging data from its successfully completed European clinical trial of GelrinC, demonstrating that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage. The analysis was conducted by Prof. Siegfried Trattnig of Vienna University and his colleagues, global leaders in cartilage MRI imaging, using validated methodologies accepted by both U.S. FDA and Europe's EMA regulators, further strengthening the translational and regulatory relevance of the findings. As an innovative regenerative medical product, GelrinC offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.공시 • Jan 08+ 1 more updateRegentis Biomaterials Ltd. Gelrinc Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART EvaluationRegentis Biomaterials Ltd. announced publication of long-term follow-up results from its successfully concluded Phase II clinical trial of GelrinC in the peer-reviewed journal Cartilage. The study, led by Prof. Siegfried Trattnig of Vienna University and colleagues, reports strong radiologic evidence of durable cartilage regeneration at 24 months. Regentis is the first company to extensively use MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue), a validated MRI-based quantitative measure of cartilage quantity and quality as a secondary endpoint in a clinical study, and to have the U.S. Food and Drug Administration’s (FDA) acceptance of this approach. In contrast to the predominantly subjective clinical endpoints commonly used in cartilage repair studies, Regentis deliberately selected objective, imaging-based endpoints as a rigorous measure of structural repair from the outset. Regentis is unique in having predefined MOCART as a prospective imaging and primary endpoint built into the protocol from day one, and in having the MOCART assessments conducted by the Vienna University-based team that developed the method which is widely regarded as the gold standard. As such, Regentis is advancing what it believes is a more rigorous standard for assessing cartilage regeneration by emphasizing objective, quantitative structural outcomes alongside the current standard of care KOOS (Knee Injury and Osteoarthritis Outcome Score) which is a questionnaire-based patient-reported measure of pain. In practice, these results mean that two years after treatment, the repaired cartilage appears very close to normal, healthy cartilage based on objective MRI assessment. Importantly, the imaging shows ongoing tissue maturation over time, supporting the durability of the repair. GelrinC is currently being evaluated in a pivotal Phase III U.S. Food and Drug Administration investigational device exemption (IDE) study designed to support a future premarket approval (PMA) submission, with 80 patients and two-year follow-up as part of the core study design. Regentis has achieved over 50% enrollment.공시 • Dec 04Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million.Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,250,000 Price\Range: $8 Discount Per Security: $0.56 Transaction Features: Sponsor Backed OfferingNew Risk • Nov 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$1.78m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$987k free cash flow). Shares are highly illiquid. Negative equity (-US$9.2m). Revenue is less than US$1m. Market cap is less than US$10m (US$1.78m market cap).Board Change • Sep 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Keith Valentine was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.이익 및 매출 성장 예측NYSEAM:RGNT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2026N/AN/AN/AN/A112/31/2025N/A-14-1-1N/A9/30/2025N/A-7-1-1N/A6/30/2025N/A0-1-1N/A3/31/2025N/A0-1-1N/A12/31/2024N/A0-1-1N/A9/30/2024N/A0-1-1N/A6/30/2024N/A000N/A3/31/2024N/A-2-1-1N/A12/31/2023N/A-4-1-1N/A6/30/2023N/A-4-2-2N/A3/31/2023N/A-3-2-2N/A12/31/2022N/A-1-2-2N/A6/30/2022N/A-6-1-1N/A3/31/2022N/A-5-1-1N/A12/31/2021N/A-500N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: RGNT 의 예상 수익 증가율이 절약률(3.5%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: RGNT 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: RGNT 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: RGNT 의 수익이 US 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: RGNT 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: RGNT의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/18 00:18종가2026/06/18 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Regentis Biomaterials Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ashok KumarThinkEquity LLC
공시 • 12hRegentis Biomaterials Ltd. announced that it expects to receive $6.5 million in fundingRegentis Biomaterials Ltd. entered into definitive securities purchase agreements with certain accredited and institutional investors for issuance of 1,844,543 common shares at a price of $3.50 per share for gross proceeds of $6,455,900.50; and 12,600 pre-funded warrants at a price of $3.4999 per pre-funded warrant for gross proceeds of $44,098.74; for aggregate gross proceeds of $6,499,999.24 on June 17, 2026. The company will also issue ordinary warrants to purchase up to 1,857,143 ordinary shares. The pre-funded warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable upon issuance and will not expire until exercised in full. The ordinary warrants have an exercise price of $4.20 per ordinary share, are immediately exercisable upon issuance and will expire on the five-year anniversary from the date of issuance. The offering is expected to close on or about June 23, 2026. The ordinary shares, the warrants and the ordinary shares issuable upon exercise of the warrants were offered and sold pursuant to an exemption from the registration requirements of the securities act of 1933, as amended, under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D promulgated thereunder.
공시 • Jun 15Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21
공시 • Jun 09Regentis Biomaterials Ltd. Commences European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations AccelerateRegentis Biomaterials Ltd. announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC in Europe, where it has CE Mark approval. The hands-on training program is designed to train orthopedic surgeons in the use of GelrinC, providing practical experience with the implantation procedure and supporting physician readiness ahead of market launch. The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital. Additional sessions are planned in other European markets. GelrinC is a cell-free implant for the treatment of knee cartilage lesions. The procedure utilizes a ready-to-use implant and a straightforward single-step implantation process, which takes approximately 10 minutes, and fits into the surgeon's workflow. Regentis is establishing a network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC. These centers are intended to serve as clinical hubs where experienced orthopedic surgeons will help train and support other physicians across Europe as the technology is introduced into clinical practice. Regentis is targeting an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus standard of care microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration study, which has completed over 50% enrollment.
공시 • May 29Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026. Location: apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal, tel aviv, Israel
New Risk • May 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$10.00m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$10.00m market cap).
공시 • May 03Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million.Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,334 Price\Range: $3 Discount Per Security: $0.21
New Risk • Feb 26New major risk - Revenue and earnings growthEarnings have declined by 5.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$20.7m market cap).
공시 • Feb 04+ 1 more updateRegentis Biomaterials Ltd. Announces the Appointment of Ori Gon as Chief Financial Officer, Effective February 4, 2026Regentis Biomaterials Ltd. announced the appointment of Ori Gon as Chief Financial Officer, effective February 4, 2026. Mr. Gon will lead the Company's commercial and business development activities, as well as its financial strategy, planning, and reporting. Mr. Gon joins Regentis at a pivotal time as GelrinC®, the Company's proprietary hydrogel implant for knee cartilage repair, advances towards commercial launch in Europe following CE Mark approval and is being evaluated in a pivotal Phase III FDA clinical trial in the United States. Mr. Gon brings over 15 years of financial leadership experience across public and private enterprises and medical technology. Most recently, he served as CFO at Tactile Mobility, a sensing and data analytics company focused on advanced automotive and mobility applications. Prior to that, he held senior financial leadership roles at ReWalk Robotics Inc., now Nasdaq-listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons for individuals with lower limb disabilities, where he served as CFO and Corporate Controller. Earlier in his career, he was Controller at On Track Innovations Ltd., a Nasdaq- and Neuer Markt-listed fintech company. He began his professional career as an auditor at KPMG Israel. Mr. Gon has led multiple secondary public offerings and financing transactions across various structures, raising over $150 million in aggregate capital. He is a Certified Public Accountant (CPA) in Israel.
공시 • Jan 21Regentis Biomaterials Ltd. Announces New Long-Term Imaging Data from Its Successfully Completed European Clinical Trial of GelrinCRegentis Biomaterials Ltd. announced new long-term imaging data from its successfully completed European clinical trial of GelrinC, demonstrating that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage. The analysis was conducted by Prof. Siegfried Trattnig of Vienna University and his colleagues, global leaders in cartilage MRI imaging, using validated methodologies accepted by both U.S. FDA and Europe's EMA regulators, further strengthening the translational and regulatory relevance of the findings. As an innovative regenerative medical product, GelrinC offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.
공시 • Jan 08+ 1 more updateRegentis Biomaterials Ltd. Gelrinc Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART EvaluationRegentis Biomaterials Ltd. announced publication of long-term follow-up results from its successfully concluded Phase II clinical trial of GelrinC in the peer-reviewed journal Cartilage. The study, led by Prof. Siegfried Trattnig of Vienna University and colleagues, reports strong radiologic evidence of durable cartilage regeneration at 24 months. Regentis is the first company to extensively use MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue), a validated MRI-based quantitative measure of cartilage quantity and quality as a secondary endpoint in a clinical study, and to have the U.S. Food and Drug Administration’s (FDA) acceptance of this approach. In contrast to the predominantly subjective clinical endpoints commonly used in cartilage repair studies, Regentis deliberately selected objective, imaging-based endpoints as a rigorous measure of structural repair from the outset. Regentis is unique in having predefined MOCART as a prospective imaging and primary endpoint built into the protocol from day one, and in having the MOCART assessments conducted by the Vienna University-based team that developed the method which is widely regarded as the gold standard. As such, Regentis is advancing what it believes is a more rigorous standard for assessing cartilage regeneration by emphasizing objective, quantitative structural outcomes alongside the current standard of care KOOS (Knee Injury and Osteoarthritis Outcome Score) which is a questionnaire-based patient-reported measure of pain. In practice, these results mean that two years after treatment, the repaired cartilage appears very close to normal, healthy cartilage based on objective MRI assessment. Importantly, the imaging shows ongoing tissue maturation over time, supporting the durability of the repair. GelrinC is currently being evaluated in a pivotal Phase III U.S. Food and Drug Administration investigational device exemption (IDE) study designed to support a future premarket approval (PMA) submission, with 80 patients and two-year follow-up as part of the core study design. Regentis has achieved over 50% enrollment.
공시 • Dec 04Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million.Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,250,000 Price\Range: $8 Discount Per Security: $0.56 Transaction Features: Sponsor Backed Offering
New Risk • Nov 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$1.78m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$987k free cash flow). Shares are highly illiquid. Negative equity (-US$9.2m). Revenue is less than US$1m. Market cap is less than US$10m (US$1.78m market cap).
Board Change • Sep 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Keith Valentine was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.